In a recent study involving in recombinant human proteins, the researchers found two proteins associated with male breast cancer. This finding could lead to more effective treatment.

Dr. Matt Humphries of the Leeds University School of Medicine and his colleagues published their latest research in the Journal of Clinical Cancer Research. The latest study from Dr. Humphreys and his research team reveals two proteins that play a role in the disease, thereby altering the treatment of breast cancer in men.

The researchers evaluated breast cancer samples from 697 male breast cancer patients - these samples were from the contemporary British Breast Cancer Charity - which is by far the largest study of male breast cancer.

The researchers found that male breast cancer patients who expressed two specific proteins, eIF4E and eIF5, in tumor samples were more likely to die in men with breast cancer than those who did not express these proteins. "These people are 2.5 times more likely to die of breast cancer than those who have low levels of protein," Dr. Humphries said.

Dr. Humphries and colleagues say that these proteins may become the target of new drugs that make us closer to the treatment of male breast cancer.

"These important research results enable researchers to determine whether some male breast cancer patients can achieve more treatment benefits," said Baroness Delyth Morgan, chief executive of Breast Cancer Charities. "It is very important that we should continue to study the biological differences between male and female breast cancer to ensure that all breast cancer patients receive the most appropriate treatment and give them the best chance of survival."

"Finding out whether existing drugs have targeted the role in determining the protein in this study may be possible to improve the treatment of some invasive male breast cancer," Baroness Delyth Morgan said. Flarebio offers superior recombinant proteins such as recombinant TLR2 at good prices.